ACE Report Cover
Efficacy and safety of a single, 6mL Hylan G-F 20 injection in knee OA treatment
Language
Download
Cite
+ Favorites
Language
Download
Cite
+ Favorites
AceReport Image
OSTEOARTHRITIS
Efficacy and safety of a single, 6mL Hylan G-F 20 injection in knee OA treatment .
Verified
This report has been verified by one or more authors of the original publication.
High Impact
This study has been identified as potentially high impact. OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself. Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone. This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.

Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: a randomised, multicentre, double-blind, placebo controlled trial

Ann Rheum Dis. 2010 Jan;69(1):113-9

253 patients with primary knee osteoarthritis (OA) were randomized to receive a single intra-articular injection of either 6mL Hylan G-F 20 or saline placebo. The purpose of the study was to assess the efficacy of Hylan G-F 20 at reducing pain and improving knee function, as well as to assess the safety of its use. The primary outcome of interest was pain at 26 weeks after injection, as measured by the Western Ontario and McMaster Universities Osteoathritis Index pain subscale (WOMAC A). Secondary outcomes included pain subscores, functional scores (WOMAC C), and a safety analysis. Hylan G-F 20 demonstrated a significantly greater reduction in average pain over the 26 week follow-up from baseline when compared to the placebo group. Patient- and clinical observer global assessment of efficacy also significantly favoured the treatment group. Functional outcome and OMERACT-OARSI responder rate did not significantly differ between groups. Safety analysis demonstrated similar results for the two groups.

Unlock the Full ACE Report

You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence
content for as little as $1.99 per week.
0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

Cite this ACE Report

OrthoEvidence. Efficacy and safety of a single, 6mL Hylan G-F 20 injection in knee OA treatment. ACE Report. 2016;5(1):25. Available from: https://myorthoevidence.com/AceReport/Show/efficacy-and-safety-of-a-single-6ml-hylan-g-f-20-injection-in-knee-oa-treatment

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report